Effect of a new ultrashort betalytic agent on aconitine-induced arrhythmia.

Abstract

The anti-arrhythmic effect was tested on the model of aconitine-induced arrhythmia. The experiment was performed in vivo with 31 male Wistar laboratory rats. Group A was first administered aconitine and, after the onset of the first sinus rhythm disorders, the 44Bu compound was administered. Group B was first administered the 44Bu compound and only after that the aconitine. The control group was administered aconitine and saline as a replacement of the tested compound. In group A, there was a decrease in the ventricular fibrillation occurrence from 100 % to 8 % (p < 0.001) after the administration of the 44Bu compound. In the B group, the onsets of all monitored arrhythmia types were delayed by an average of 15.6 min. Ventricular rhythm occurrence was decreased from 100 to 20 %, as well as ventricular fibrillations, from 100 to 0 % (p < 0.001).

• Authors: Ladislava Bartosová, Filip Novák, Marek Frydrych, Tomás Parák, Radka Opatrilová, Vít Brunclík, Jana Kolevská, Elnaggar El Moataz, Jirí Necas
• Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub) Vol. 149 Issue 2 Pg. 339-43 (Dec 2005) ISSN: 1213-8118 [Print] Czech Republic
• PMID: 16601784 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenergic beta-Antagonists
• Anti-Arrhythmia Agents
• Benzoates
• Aconitine

Topics

• Aconitine (toxicity)
• Adrenergic beta-Antagonists (therapeutic use)
• Animals
• Anti-Arrhythmia Agents (therapeutic use)
• Arrhythmias, Cardiac (chemically induced, drug therapy)
• Benzoates (therapeutic use)
• Drug Evaluation, Preclinical
• Male
• Rats
• Rats, Wistar